Cyclooxygenase-2-derived prostacyclin regulates arterial thrombus formation by suppressing tissue factor in a sirtuin-1-dependent-manner
| Autor: | Patrizia Amadio, Silvia S. Barbieri, Eva Tarantino, Babette B. Weksler, Elena Tremoli, Sara Gianellini, Louise R. Howe, Elena Zacchi, Luciana Mussoni, Fabrizio Veglia |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Blood Platelets
Male medicine.medical_specialty Prostacyclin Receptors Epoprostenol Ferric Compounds Prostacyclin synthase Thromboplastin Tissue factor Mice Chlorides Sirtuin 1 Risk Factors Physiology (medical) Internal medicine medicine Animals Platelet Carotid Artery Thrombosis PPAR delta Prostacyclin receptor Mice Knockout biology business.industry Incidence Epoprostenol Mice Inbred C57BL Endocrinology Cyclooxygenase 2 Models Animal biology.protein Peroxisome proliferator-activated receptor delta Cyclooxygenase Cardiology and Cardiovascular Medicine business medicine.drug Signal Transduction |
| Zdroj: | Circulation. 126(11) |
| ISSN: | 1524-4539 |
| Popis: | Background— Selective inhibitors of cyclooxygenase (COX)-2 increase the risk of myocardial infarction and thrombotic events, but the responsible mechanisms are not fully understood. Methods and Results— We found that ferric chloride–induced arterial thrombus formation was significantly greater in COX-2 knockout compared with wild-type mice. Cross-transfusion experiments excluded the likelihood that COX-2 knockout platelets, despite enhanced aggregation responses to collagen and thrombin, are responsible for increased arterial thrombus formation in COX-2 knockout mice. Importantly, we observed that COX-2 deletion decreased prostacyclin synthase and production and peroxisome proliferator-activated receptor- and sirtuin-1 (SIRT1) expression, with consequent increased upregulation of tissue factor (TF), the primary initiator of blood coagulation. Treatment of wild-type mice with a prostacyclin receptor antagonist or a peroxisome proliferator-activated receptor-δ antagonist, which predisposes to arterial thrombosis, decreased SIRT1 expression and increased TF activity. Conversely, exogenous prostacyclin or peroxisome proliferator-activated receptor-δ agonist completely reversed the thrombotic phenotype in COX-2 knockout mice, restoring normal SIRT1 levels and reducing TF activity. Furthermore, inhibition of SIRT1 increased TF expression and activity and promoted generation of occlusive thrombi in wild-type mice, whereas SIRT1 activation was sufficient to decrease abnormal TF activity and prothrombotic status in COX-2 knockout mice. Conclusions— Modulation of SIRT1 and hence TF by prostacyclin/peroxisome proliferator-activated receptor-δ pathways not only represents a new mechanism in controlling arterial thrombus formation but also might be a useful target for therapeutic intervention in the atherothrombotic complications associated with COX-2 inhibitors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|